acetovanillone has been researched along with Parkinson Disease, Secondary in 2 studies
apocynin : An aromatic ketone that is 1-phenylethanone substituted by a hydroxy group at position 4 and a methoxy group at position 3.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, L | 1 |
| Chen, L | 1 |
| Wei, X | 1 |
| Wang, Y | 1 |
| Ren, Z | 1 |
| Zeng, S | 1 |
| Zhang, X | 1 |
| Wen, H | 1 |
| Gao, C | 1 |
| Liu, H | 1 |
| Sharma, N | 1 |
| Kapoor, M | 1 |
| Nehru, B | 1 |
2 other studies available for acetovanillone and Parkinson Disease, Secondary
| Article | Year |
|---|---|
NOD2 promotes dopaminergic degeneration regulated by NADPH oxidase 2 in 6-hydroxydopamine model of Parkinson's disease.
Topics: Acetophenones; Animals; Apomorphine; Cell Line, Transformed; Corpus Striatum; Disease Models, Animal | 2018 |
Apocyanin, NADPH oxidase inhibitor prevents lipopolysaccharide induced α-synuclein aggregation and ameliorates motor function deficits in rats: Possible role of biochemical and inflammatory alterations.
Topics: Acetophenones; alpha-Synuclein; Animals; Behavior, Animal; Cytokines; Disease Models, Animal; Dopami | 2016 |